Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Separation or purification
Reexamination Certificate
2003-09-22
2008-12-30
Desai, Anand U (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Separation or purification
C514S002600
Reexamination Certificate
active
07470779
ABSTRACT:
The present invention is directed generally to recombinant methods for making a desired pegylated protein and pooling of same. The method(s) yield a polypeptide product containing reduced levels of aggregate thereof pooled to provide the desired pegylated isoforms thereof.
REFERENCES:
patent: 5149647 (1992-09-01), Burling
patent: 5153265 (1992-10-01), Shadle et al.
patent: 5290685 (1994-03-01), Koide et al.
patent: 5849535 (1998-12-01), Cunningham et al.
patent: 5969109 (1999-10-01), Bona et al.
patent: 6057292 (2000-05-01), Cunningham et al.
patent: 6096870 (2000-08-01), Mozaffar et al.
patent: 2002/0037841 (2002-03-01), Papadimitriou
patent: 2003/0171285 (2003-09-01), Finn et al.
patent: WO 96/02570 (1996-02-01), None
patent: WO 96 40731 (1996-12-01), None
patent: WO 02/057478 (2002-07-01), None
Olson et al., “Chapter 12: Preparation and Characterization of Poly(ethylene glycol)ylated Human Growth Hormone Antagonist”, pp. 170-181, Poly(ethylene glycol): chemistry and biological applications, J. Milton Harris, editor, Samuel Zalipsky, editor, (1997).
Pharmacia Fine Chemicals, “Chapter 2: Ion Exchange Chromatography, principles and methods”, (1980).
Andersson et al., “Isolation and characterization of a trisulfide variant of recombinant human growth hormone formed during expression inEscherichia coli,” Int. J. Peptide Protein Res. 47:311-321 (1996).
J. Houk and G.M. Whitesides, “Structure-Reactivity Relations for Thiol-Disulfide Interchange,” J. M. Chem. Soc., 109:6825-6836 (1987).
A. Jesperson et al., “Characterisation of a trisulphide derivative of biosynthetic human growth hormone produced inEscherichia coli,” Eur. J. Biochem. 219:365-373 (1994).
Jorgensen et al., “Quantifying biosynthetic human growth hormone inEscherichia coliwith electrophoresis under hydrophobic conditions,” J. Chromatography A 817:205-214 (1998).
The Merck Index, 12thEdition, S. Budavari (Editor), Merck & Co., Inc., Therapeutic Category and Biological Activity Index, p. THER-19 (under “Chelating Agent”), Whitehouse Station, NJ (1996).
Aykent Serdar
Boyle Denis M.
Buckley John J.
Johnson Gary V.
Rathore Anurag S.
Benson Gregg C.
Desai Anand U
Pfizer Inc.
Slepchuk Nicholas I.
LandOfFree
Process for decreasing aggregate levels of pegylated protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for decreasing aggregate levels of pegylated protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for decreasing aggregate levels of pegylated protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4020708